Abciximab
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
tinzaparin
Low-molecular-weight heparin · Anticoagulant
Low-molecular-weight heparinAnticoagulant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
B
FDA category + note
Top interactionssee all 12 →
- AbciximabSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AlteplaseSevereDatabaseDDInter
- AnagrelideSevereDatabaseDDInter
Mechanism
Low-molecular-weight heparins bind to antithrombin and accelerate the rate at which it inhibits various coagulation proteases, particularly factor Xa. At least half of the molecules are too short to provide bridging function and have no effect on the rate of thrombin inhibition by antithrombin.
Indications
maintenance treatment in patients with cancer-associated venous thromboembolismVTE
Dosing
- Pediatric
- May require monitoring
- Renal adjustment
- May require monitoring with an anti–factor Xa assay due to accumulation and bleeding risk. Contraindicated in patients with creatinine clearance below 30 mL/min.
Pharmacokinetics
Half-life
4-6 hours
Bioavailability
90% after subcutaneous injection
Excretion
Cleared almost exclusively by the kidneys
Contraindications
- Creatinine clearance below 30 mL/min
Side effects
Common
Bleeding (somewhat less incidence than unfractionated heparin)Little effect on plateletsReversible abnormalities of hepatic function tests
Serious
- Thrombocytopenia (<1% incidence)
- Osteoporosis (lower risk than unfractionated heparin)
- Hyperkalemia
Pregnancy & lactation
Pregnancy
B
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alteplase
Severe
Database
Clinical effect not specified
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Antithrombin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Iii Human
Severe
Database
Clinical effect not specified
Source: DDInter
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Argatroban
Severe
Database
Clinical effect not specified
Source: DDInter
Aspirin
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Betrixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bivalirudin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Low-molecular-weight heparin drugs
Ask House about tinzaparin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team